In the Prologue, Eban strategically employs the narration of Peter Baker’s FDA inspection at Wockhardt Ltd. to introduce crucial facts and key persons that form the foundation for the book’s exploration of the pharmaceutical industry. Baker, as an FDA investigator, becomes a central figure whose stringent approach sets the tone for the narrative. Eban also establishes the significance of overseas inspections, highlighting the contrast between unannounced visits to US-based plants and the advance notice typically given to overseas facilities. This distinction emphasizes the challenges and advantages faced by investigators in their pursuit of uncovering the truth behind generic drug manufacturing, introducing the theme of Corporate Attitudes and Regulation.

Eban presents Baker as a deviation from the norm within the pharmaceutical inspection landscape. Unlike the usual practice, where companies can manipulate appearances and present a facade of compliance, Eban depicts Baker as cutting through these executive-led presentations: “Unlike so many other FDA investigators, he was hard to prepare for—and control […] He seemed to be everywhere at once. He studied the employees for signs of evasion as he questioned them repeatedly” (4). His persistence and thoroughness expose the discrepancies that often go unnoticed during routine inspections, introducing the book’s broader exploration of the compromised practices within the pharmaceutical industry and The Importance of Manufacturing Safeguards, hinting at the need for a more vigilant approach toward drug safety.

The incident where Baker and another investigator chase down a suspicious employee also foreshadows the high-stakes nature of the pharmaceutical industry, where The Consequences of Cost-Cutting and Speed can potentially compromise patient safety. The chase sequence becomes a microcosm of the larger narrative, emphasizing the relentless pursuit of truth and accountability in an industry where deception and manipulation are not uncommon.

Through the Prologue, Eban effectively establishes the stakes of Bottle of Lies. She describes a sterile laboratory with utmost care: “One small slip—a failure to filter air properly, a misreading of bacterial samples, the exposed wrist of a technician—could result in a contaminated product that would kill instead of cure” (3, emphasis added). As Eban stresses, patient safety is at risk when things go wrong with drug manufacturing, and the financial and reputational implications for drug companies add an extra layer of urgency to the narrative.